atenolol has been researched along with digoxin in 42 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (4.76) | 18.7374 |
1990's | 8 (19.05) | 18.2507 |
2000's | 11 (26.19) | 29.6817 |
2010's | 14 (33.33) | 24.3611 |
2020's | 7 (16.67) | 2.80 |
Authors | Studies |
---|---|
Artursson, P; Neuhoff, S; Ungell, AL; Zamora, I | 1 |
Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S | 1 |
Abraham, MH; Acree, WE; Ibrahim, A | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Avdeef, A; Tam, KY | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
Ahuja, VT; Allen, J; Bristow, LJ; Bronson, JJ; Brown, JM; Camac, D; Dandapani, K; Dokania, M; Dzierba, CD; Easton, A; Elavazhagan, S; Gulianello, M; Hamman, BD; Hartz, RA; Hunihan, L; Kiefer, SE; Kostich, W; Kumar, CMV; Lewis, M; Lippy, JS; Macor, JE; Muckelbauer, JK; Nara, SJ; Pattipati, SN; Rajamani, R; Surti, N | 1 |
Hu, J; Hu, Q; Kong, X; Liu, J; Luo, G; Shen, H; Wang, C; Wu, T; Wu, X; Xiang, Q; Xu, Y; Zhang, C; Zhang, Y; Zhuang, X; Zou, L | 1 |
Hu, J; Hu, Q; Liu, J; Luo, G; Wang, C; Wu, S; Wu, T; Xiang, Q; Xu, H; Xu, J; Xu, Y; Zhang, C; Zhang, M; Zhang, Y; Zhuang, X | 1 |
Fantini, G; Mattioli, AV; Mattioli, G; Modena, MG | 1 |
Henry, M; Kay, MM; Viccellio, P | 1 |
Buch, J; Hansen, PB; Rasmussen, OO; Steiness, E; Waldorff, S | 1 |
Channer, KS; James, MA; MacConnell, T; Rees, JR | 1 |
Castillo, G; Lanas, F; Molina, E; Montecinos, A; Salvatici, R; Stockins, B | 1 |
Albert, D; Brugada, J; Brugada, R; Casaldàliga, J; Domingo, A; Girona, J; Mont, L | 1 |
Camm, AJ; Guo, X; Hnatkova, K; Malik, M; Murgatroyd, FD | 1 |
Camm, AJ; Gallagher, MM; Guo, X; Hnatkova, K; Malik, M; Murgatroyd, FD; Waktare, JE | 1 |
Camm, AJ; Guo, X; Hnatkova, K; Malik, M; Murgatroyd, FD; Waktare, JE | 1 |
Farshi, R; Kistner, D; Longmate, JA; Sarma, JS; Singh, BN | 1 |
Akalin, H; Aral, A; Eryilmaz, S; Inan, MB; Sirlak, M; Tasoz, R; Yazicioglu, L | 1 |
Côté, E; Good, L; Wright, KN | 1 |
Bass, EB; Tamariz, LJ | 1 |
Del Giaccio, A; Eblen-Zajjur, A | 1 |
Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K | 1 |
Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC | 1 |
Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M | 1 |
Fletcher, S; Gharanei, M; James, RS; Maddock, H; Wallis, R | 1 |
Chang, H; Chen, C; Du, H; Guan, C; Li, C; Qiu, L; Wang, S; Wang, T; Wu, Y; Zhang, L; Zhang, S; Zhou, H | 1 |
3 review(s) available for atenolol and digoxin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological rate control of atrial fibrillation.
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diltiazem; Heart Rate; Humans; Metoprolol; Randomized Controlled Trials as Topic; Verapamil | 2004 |
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Atrioventricular Node; Bradycardia; Calcium Channel Blockers; Cardiac Resynchronization Therapy; Catheter Ablation; Digoxin; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Pacemaker, Artificial; Patient-Centered Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sotalol | 2016 |
8 trial(s) available for atenolol and digoxin
Article | Year |
---|---|
Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Atenolol; Atrial Fibrillation; Bradycardia; Digoxin; Drug Synergism; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Middle Aged; Pindolol; Single-Blind Method | 1994 |
Graphical representation of complex data--diurnal patterns of initiations of atrial fibrillation episodes.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Circadian Rhythm; Computer Graphics; Cross-Over Studies; Digoxin; Disopyramide; Double-Blind Method; Electrocardiography, Ambulatory; Female; Humans; Male; Middle Aged; Probability | 1997 |
Evolution of changes in the ventricular rhythm during paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxin; Disopyramide; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Time Factors | 1998 |
Age and gender influences on rate and duration of paroxysmal atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Cross-Over Studies; Digoxin; Disopyramide; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Sex Factors; Signal Processing, Computer-Assisted; Time Factors | 1998 |
Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
Topics: Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Calcium Channel Blockers; Circadian Rhythm; Cross-Over Studies; Digoxin; Diltiazem; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise; Female; Follow-Up Studies; Heart Rate; Heart Ventricles; Humans; Male; Middle Aged | 1999 |
The effect of preoperative digitalis and atenolol combination on postoperative atrial fibrillation incidence.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Coronary Artery Bypass; Digoxin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Postoperative Complications; Premedication | 2002 |
Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Cardiovascular Diseases; Cross-Sectional Studies; Digoxin; Female; Humans; Male; Middle Aged; Nociceptors; Pindolol; Propranolol; Young Adult | 2010 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Digoxin; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipoproteins, HDL; Losartan; Male; Middle Aged; Risk | 2015 |
31 other study(ies) available for atenolol and digoxin
Article | Year |
---|---|
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Membrane Permeability; Digoxin; Drug Interactions; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Pharmaceutical Preparations; Pharmacokinetics | 2003 |
Exploring the role of different drug transport routes in permeability screening.
Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2005 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Caco-2 Cells; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Neuralgia; Protein Kinases; Protein Serine-Threonine Kinases; Structure-Activity Relationship | 2021 |
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; CREB-Binding Protein; Drug Design; Humans; Indolizidines; Male; Mice; Mice, SCID; Microsomes, Liver; Models, Molecular; Molecular Docking Simulation; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2022 |
Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carrier Proteins; Cell Line, Tumor; DNA-Binding Proteins; Humans; Male; Prostatic Neoplasms; Protein Domains | 2022 |
Atenolol in dilated cardiomyopathy: a clinical instrumental study.
Topics: Atenolol; Cardiomyopathy, Dilated; Digoxin; Diuretics; Drug Therapy, Combination; Echocardiography; Female; Humans; Male; Middle Aged | 1990 |
Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Calcium Channel Blockers; Calcium Chloride; Digoxin; Diltiazem; Female; Humans; Isoproterenol; Male; Shock, Cardiogenic; Verapamil | 1985 |
Influence of atenolol and nifedipine on digoxin-induced inotropism in humans.
Topics: Adult; Atenolol; Blood Pressure; Creatinine; Digoxin; Drug Interactions; Electrocardiography; Female; Heart Rate; Hemodynamics; Humans; Kidney Function Tests; Male; Myocardial Contraction; Nifedipine | 1984 |
[Comparison between digoxin and atenolol in chronic atrial fibrillation].
Topics: Adult; Aged; Analysis of Variance; Atenolol; Atrial Fibrillation; Blood Pressure; Chronic Disease; Cross-Over Studies; Digoxin; Ergometry; Female; Heart Rate; Humans; Male; Middle Aged; Physical Exertion; Random Allocation; Rest; Ventricular Function, Right | 1995 |
[Familial auricular fibrillation].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atenolol; Atrial Fibrillation; Digoxin; Echocardiography; Electrocardiography; Female; Humans; Male; Middle Aged; Pedigree; Propafenone | 1997 |
ECG of the month. Narrow-complex monomorphic tachycardia with a ventricular rate of 320 beats/min.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Diagnosis, Differential; Digoxin; Dog Diseases; Dogs; Electrocardiography; Fatal Outcome; Female; Heart Rate; Histiocytic Sarcoma; Tachycardia | 2002 |
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diuretics; Electrocardiography; Enalapril; Female; Furosemide; Heart Failure; Isosorbide Dinitrate; Male; Mice; Mitochondria, Heart; Spironolactone | 2017 |
The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles.
Topics: Animals; Anthropometry; Atenolol; Cardiotonic Agents; Digoxin; Dobutamine; Electric Stimulation; Flecainide; In Vitro Techniques; Isometric Contraction; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Verapamil | 2020 |
Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats.
Topics: Animals; Antipyrine; Atenolol; Carbamazepine; Cell Membrane; Digoxin; Diltiazem; Diphenhydramine; Drug Elimination Routes; Gabapentin; Lamotrigine; Liver; Memantine; Membrane Transport Proteins; Microdialysis; Muscle, Skeletal; Ofloxacin; Pharmaceutical Preparations; Propranolol; Pyrilamine; Quinidine; Rats; Terfenadine | 2021 |